CYP2D6 is a key pharmacogene encoding an enzyme impacting poor, intermediate, extensive and ultrarapid phase I metabolism of many marketed drugs. The pharmacogenetics of opiate drug metabolism is particularly interesting due to the relatively high incidence of addiction and overdose. Recently, trans-acting opiate metabolism and analgesic response enzymes (UGT2B7, ABCB1, OPRM1 and COMT) have been incorporated into pharmacogenetic studies to generate more comprehensive metabolic profiles of patients. With use of massively parallel sequencing, it is possible to identify additional polymorphisms that fine tune, or redefine, previous pharmacogenetic findings, which typically rely on targeted approaches. The 1000 Genomes Project data were analyzed to describe population genetic variation and statistics for these five genes in self-reported healthy individuals in five global super-and 26 sub-populations. Findings on the variation of these genes in various populations expand baseline understanding of pharmacogenetically relevant polymorphisms for future studies of affected cohorts. 
INTRODUCTION
Cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) is a clinically significant enzyme responsible for~30% of phase I metabolism of~25% of marketed drugs. 1, 2 Of particular interest is the enzyme's role in the conversion of pain medications to active metabolites, namely morphine. [3] [4] [5] The highly polymorphic nature of CYP2D6 results in various metabolizer phenotypes (MP; poor (PM), intermediate (IM), extensive (EM) and ultra-rapid (UM)), [6] [7] [8] typically inferred from the diplotype of CYP2D6 star (*) alleles (a haplotype of one or more polymorphisms along the length of the gene), 9 that have been associated with lack of therapeutic response, idiosyncratic responses, or even death. [10] [11] [12] Comprehensive pharmacogenetic studies have shown that single-nucleotide polymorphisms (SNPs) in other opiate metabolism and pain relief pathway genes also confer variable degrees of enzyme activity. [13] [14] [15] [16] [17] These additional genes of interest include uridine diphosphate glucuronosyltransferase, family 1, polypeptide B7 (UGT2B7), adenosine triphosphate-binding cassette, subfamily B, number 1 (ABCB1), opioid receptor mu 1 (OPRM1) and catechol-O-methyltransferase (COMT). UGT2B7 encodes an enzyme that converts morphine to morphine-6-glucuronide; these two compounds are the primary cause of the analgesic effect of opiates. ABCB1 encodes p-glycoprotein (or multidrug resistance protein 1), a membrane-associated transporter responsible for the efflux of morphine from various organs. OPRM1 encodes the primary receptor for signal transduction of the analgesic response. Finally, COMT encodes a protein that interacts with the opioid receptor mechanism to modulate pain response through catecholamine breakdown. Polymorphisms within these genes can impact opiate metabolism by altering the performance of their protein products, leading to non-effective treatment or clinical complications following opiate medication administration. 14, 15 Previous pharmacogenetic studies have focused on identifying common causal polymorphisms using genome-wide association studies (targeted SNP arrays and targeted massively parallel sequencing) to determine the MP of ante-and post-mortem patients. [17] [18] [19] While valuable, these methods fail to assess polymorphisms comprehensively in a target sequence on the individual and population levels. In addition, they hinder discovery of novel polymorphisms that may provide greater insight into phenotypic variability and subsequent resequencing of target loci 1 may be required for confirmation of allele calls. 20 Massively parallel sequencing of the full gene region may reveal additional variants, with reliable depth of coverage, which refine the current working knowledge of CYP2D6 * alleles, for example, those which introduce premature stop codons before the defining polymorphisms of a * allele.
Pharmacogenetic population studies often control for presence of disease phenotype while placing less emphasis on demography and population substructure as contributing factors to variable allele distribution which may confer different metabolic profiles in populations. 10, 21, 22 Consequently, false positive associations may arise regarding the relationship between genotype and MP. 23 Herein, an in silico study of the complete gene sequences of CYP2D6, UGT2B7, ABCB1, OPRM1, COMT and their respective promoter regions was performed to identify novel SNPs, insertion/deletion (INDEL) polymorphisms and copy number variants (CNVs), define baseline population genetic variation, and identify potential phenotypic variability in opiate metabolism and pain relief. A summary is provided of population statistics, variant effect predictions, and clustering of super-and sub-populations based on SNPs, INDELs and CNVs in five genes whose protein products are associated with opiate metabolism. Finally, the distribution of CYP2D6 * alleles in five super-populations and 26 sub-populations is shown which provides additional information regarding variability within the population of EMs. 24 These findings serve as substantial population genetic data for healthy cohorts which may guide the pharmacogenetics community towards studies involving comprehensive genetic screening.
MATERIALS AND METHODS
Gene and promoter regions were identified using GeneCards Human Gene Database. 25 Genotype data were obtained from 2504 unrelated healthy individuals whose sequence data were downloaded from Phase 3 of the 1000 Genomes Project using the University of California Santa Cruz (UCSC) Table Browser 26,27 and the appropriate hg19 reference genome coordinates for CYP2D6, UGT2B7, ABCB1, OPRM1, COMT and their respective promoter regions. The 1000 Genomes Project reports data with sequence depth of coverage ≥ 4 × .
Population genetic summary statistics and statistical tests were performed for five super-populations (African (AFR), Ad Mixed American (AMR), East Asian (EAS), European (EUR) and South Asian (SAS)) and 26 subpopulation (Supplementary Table 1 ). Allele frequencies, observed and expected heterozygosity calculations, and tests for departures from HardyWeinberg equilibrium (HWE) and pairwise linkage disequilibrium (LD, assuming HWE) were performed using Genetic Data Analysis Software. 28 Allele frequency 95% confidence intervals were estimated using the normal approximation to the binomial method. Tests for HWE departures and pairwise LD were performed for super-and sub-populations due to the potential for loci meeting HWE expectations or pairwise loci linkage equilibrium in sub-populations but deviating from these expectations when pooled into super-populations. 29 Due to the size of ABCB1 and OPRM1 and the number of polymorphisms within each gene, computation constraints with software memory were experienced while performing all tests for pairwise LD between these polymorphisms (~17 million and~23 million pairwise comparisons for ABCB1 and OPRM1, respectively). Consequently, tests for pairwise LD for ABCB1 and OPRM1 polymorphisms were performed between HWE-deviating loci and all other loci. Both tests are sensitive to low frequency alleles and focusing on this subset of loci for pairwise LD testing, under the assumption of HWE, could indicate if the polymorphisms are subject to some selective pressures and/ or genotyping errors as a result of the relatively low coverage of 1000 Genomes Project data. 30 Here we use 'linkage disequilibrium block' to describe a cluster of polymorphisms with significant deviations from pairwise LD with all other polymorphisms for a gene. Ensembl Variant Predictor (Release 84, March 2016) 31 and Sort Intolerant From Tolerant (SIFT) [32] [33] [34] [35] [36] were used to determine SIFT, Polymorphism Phenotyping v2 (PolyPhen-2), 37, 38 and Protein Variant Effect Analyzer (PROVEAN) [39] [40] [41] variant effect predictions and scores for all identified polymorphisms. Intronic positions within 1000 bases of an exon were further analyzed using Human Splicing Finder (HSF). 42 Multidimensional scaling (MDS) plots and principal component analysis plots were generated in RStudio.
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CYP2D6 * alleles were assigned according to the presence of causal polymorphisms associated with known phenotype 9 and were used to assign activity scores and MP to each individual. 44 Haplotypes producing no amino acid changes and lacking causal intronic polymorphisms were considered *1; haplotypes conferring the combination of R296C and S486T amino acid changes but lacking any other amino acid change and intronic causal polymorphisms were considered *2. Individuals possessing CYP2D6 * alleles with undetermined effects on activity (*22, *28 and *43, for example), or haplotypes that could not be associated with a * allele, were removed from MP analyses. Table 3 ). When pooled, the average super-population observed heterozygosity was 0.0384 ± 0.0980 for AFR, 0.0337 ± 0.102 for AMR, 0.0281 ± 0.0918 for EAS, 0.0359 ± 0.107 for EUR and 0.0339 ± 0.107 for SAS (Table 1 and  Supplementary Table 3 ). After Bonferroni correction (Po0.000120), one locus in GBR (rs35742686), one locus in EAS (rs374153932) and four loci in AFR (rs78854695, rs28371705, rs28371703 and rs376217512) significantly deviated from HWE, all of which are less than that due to chance alone (that is,~21; Table 2 and  Supplementary Table 4) .
RESULTS

CYP2D6
After Bonferroni correction, sub-populations exhibited an average of 470 ± 90 significant pairwise LDs with a range of 331 (ASW) to 721 (KHV) significant pairwise LDs and 3693 AFR, 799 AMR, 1048 EAS, 1031 EUR and 933 SAS significant pairwise LDs were observed (P o 5.74 × 10 -7 ), all of which are less than that due to chance alone (~4358 pairwise comparisons; Table 2 and Supplementary Figure 1) . LD heat-maps of five super-populations (Supplementary Figure 2) show a cluster of six to seven polymorphisms (rs29001678 (AMR, EUR, SAS only), rs1081000, rs28695233, rs75276289, rs76312385, rs74644586 and rs1080996), which appear to form an LD block. There were an average of 44 ± 14 significant pairwise LDs between these seven polymorphisms and others within the gene, with a range of 33 (AMR) to 71 (AFR) significant pairwise LDs. This group of polymorphisms is found within CYP2D6 intron 1 (hg19 positions 42526524-42526573) and do not alter CYP2D6 function; however, rs1080995, rs74644586 and rs76312385 are part of the CYP2D6*21A haplotype and may be observed in any CYP2D6 * allele with an intron 1 gene conversion with CYP2D7 (CYP2D6*11, *14B, *21B, *63, *73, *84, *88, *98, *102, *103, *104 and *105). 9 MDS plots ( Figure 1 ) were created using CYP2D6 polymorphism pairwise genetic distances between super-populations and within super-populations (between sub-populations). There was substantial separation of the AFR and EAS populations from the cluster of AMR, EUR and SAS populations while sub-population clustering is quite diverse within each super-population.
Variant effect prediction for 418 CYP2D6 polymorphisms was performed using SIFT, PolyPhen-2 and PROVEAN (Table 3 and  Supplementary Table 5) . [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Individual polymorphisms were assigned to one of five categories based on their SIFT, PolyPhen-2 and PROVEAN scores: tolerated with no discrepancies (predictions are concordant), discrepancies but most likely tolerated (predictions are discordant but favor tolerance), discrepancies but most likely damaging (predictions are discordant but favor intolerance), damaging with no discrepancies (predictions are concordant) and conflicting results (only two scores are reported and their predictions are discordant). Summaries of their frequencies and distribution across each gene are shown in Table 3 and Figure 2a , respectively. Due to the potential for multiple alternate alleles at the 54 damaging, or most likely damaging, polymorphisms (locus rs1135830, for example, can produce a non-synonymous amino acid change or a premature stop codon), 47 single-amino acid changes, 4 premature stop codons, 2 frame-shift mutations, 1 CNV, 1 in-frame insertion and 1 in-frame deletion mutations would arise. Fifty percent (80/160) of the intronic and/or splice-associated polymorphisms were scored by HSF (Figure 2a and Supplementary Table 5 ). Seven of these loci (rs5030656, rs192358451, rs377504871, rs78854695, rs267608282, rs28371702 and rs267608275) were predicted to alter, or most likely alter, splicing of the gene. The locus rs28371702 is considered part of the haplotype for 35 * alleles although it has not been reported as functionally relevant. 9 The remaining six polymorphisms have not been reported as part of a recognized * allele. Interestingly, the four intronic polymorphisms The Human CYP Allele Nomenclature Database 9 was used to assign * alleles to each sample. 210 unique haplotypes were observed in the 1000 Genomes Project Phase 3 data set, representing 37 * alleles (Supplementary Table 6 ). The average super-population observed and expected heterozygosities were 0.72 ± 0.080 and 0.78 ± 0.091, respectively. Using * allele assignments, CYP2D6 significantly deviated from HWE expectations after Bonferroni correction in the AFR, AMR, EAS and SAS super-populations (P o 0.0348 for AFR and P = 0.0420, 0.0442 and 0.0348 in AMR, EAS and SAS, respectively) and seven subpopulations (P = 0.000200, 0.0277, 0.00290, 0.00510, 0.0202, 0.157 and 0.423 in ASW, LWK, MSL, YRI, CLM, British in England and Scotland and STU, respectively). After Bonferroni correction (P = 0.01 and P = 0.0019 for super-and sub-populations, respectively), the AFR super-population (P o 0.01) and ASW sub-population (P = 0.000200) significantly deviated from HWE expectations. Of the 210 observed haplotypes, only 14 (6.67%) are identical to those reported in the Human CYP Allele Nomenclature Table. Though not reported in the reference table, 84.8% of the remaining haplotypes could be associated with a * allele based on the presence of causal polymorphisms, however, 18 of them could not. These haplotypes represent 0.499% (25/5008) of the total 1000 Genomes Project haplotypes and contain Abbreviations: HSF, Human Splicing Finder. SIFT, PolyPhen-2 and PROVEAN score cutoffs are 0.05, 0.5 and −2.5, respectively, for distinguishing between harmful and tolerated polymorphisms. 26-35 SIFT 'damaging' and 'deleterious' predictions, and PolyPhen-2 'probably damaging' and 'possibly damaging' predictions, are qualitative classifications indicating greater and lesser degrees of confidence, respectively, in the predicted damage caused by a polymorphism. [26] [27] [28] [29] [30] [31] [32] Average HSF scores are reference (hg19) consensus score, mutant consensus score and variation score. Table 6 ). MP was assigned according to Gaedigk et al. 44 (Table 4) . A χ 2 goodness-of-fit test indicated no significant differences between observed MP frequencies of 1000 Genomes Project superpopulation data and theoretical predictions (P = 0.99), previously reported values for general United States major population groups (P = 0.54), 45 and world populations (African, American, East Asian, European and South Central Asian; P = 0.99). 24 EM individuals were used to create principal component analysis plots by population (Figure 3) . By super-population, the EM individuals display six prominent clusters with minimal overlap between AFR and EAS super-populations and considerable spread of the AMR, EUR and SAS populations across the entire plot. PC1 and PC2 explain greater than 5% of the variance for 10 and 8 polymorphisms, respectively. The same clustering pattern is observed for sub-populations with little clustering observed within populations (data not shown). The average super-population and sub-population observed and expected heterozygosities are listed in Table 1 . A full list of each polymorphism and respective population-specific observed and expected heterozygosities are shown in Supplementary  Tables 11-14. A summary of the total number of polymorphisms in each gene and population that deviated from HWE expectations is listed in Table 2 . A comprehensive list of HWE p-values for each polymorphism in each population is provided in Supplementary Tables  15-18 . After Bonferroni correction, UGT2B7 loci rs541550034 and rs57075995 (P o 8.16 × 10 ), and OPRM1 loci rs147765820, rs376391508, rs77321666 and rs111829729 (P o7.32 × 10 -6 ) deviated from HWE expectations in all five super-populations. While no COMT loci deviated from HWE expectations in the five super-populations (P = 4.97 × 10 -5 ), it should be noted that the loci rs138433986 and rs11912354 did deviate from HWE expectations in the AMR, EAS, EUR and SAS populations (P = 0.0009 and 0.0009).
One sub-population, CHB, exhibited more deviations from HWE expectations than that due to chance alone (that is,~20). A summary of the total number of pairwise loci comparisons that demonstrated significant LDs are listed in Table 2 and the distribution of LD P-values is shown in Supplementary Figures 3-6 . After Bonferroni correction, sub-populations exhibited an average of 4683 ± 4004, 9489 ± 3368, 33 303 ± 9716 and 2154 ± 1071 significant LDs for UGT2B7, ABCB1, OPRM1 and COMT, respectively. Pairwise LD heat-maps of UGT2B7, ABCB1, OPRM1 and COMT polymorphisms in five major super-populations ( Supplementary  Figures 7-10) show no substantial linkage blocks.
In contrast to CYP2D6, the individual MDS plots for UGT2B7, ABCB1, OPRM1 and COMT show substantial separation for all super-populations ( Figure 4) . Within super-populations, subpopulations cluster relatively well with minimal overlap between super-populations. Considering the entire data set of~15 000 polymorphisms, MDS plots of super-populations follow the pattern observed with single-gene plots. However, sub-populations do not show any clustering within their respective super-populations.
Variant effect prediction was performed on 613 UGT2B7, 5986 ABCB1, 6831 OPRM1 and 1007 COMT polymorphisms to generate SIFT, PolyPhen-2 and PROVEAN scores (Supplementary Tables  19-22) . [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] A summary of the average score and frequency of each variant effect is displayed in Table 3 . Of the damaging, or most likely, damaging, exonic polymorphisms in UGT2B7, ABCB1, OPRM1 and COMT, 100% (15/15, 25/25, 17/17 and 5/5 polymorphisms in UGT2B7, ABCB1, OPRM1 and COMT, respectively) are the result of single-amino acid changes. Intronic polymorphisms were analyzed further using HSF (Table 3) . Those most likely to alter splicing of UGT2B7, OPRM1 and COMT account for o5% of the total number of polymorphisms scored by HSF. The intronic polymorphisms of ABCB1 predicted to most likely, or potentially, alter splicing account for over 50% of the total (Table 3) . These polymorphisms are distributed across introns 1 through 16, with very few splice-altering polymorphisms occurring after intron 16 (Figure 2c ). In addition, one COMT polymorphism was recognized by the variant effect predictors as a frame-shift mutation (rs563298832) but was not assigned a score by the three algorithms used. Manual inspection of the locus in IGV shows the CATT deletion within intron 5 so assignment as a frame-shift mutation is incorrect. The HSF algorithm did not score this locus either. It is possible that this intronic polymorphism is damaging to the resulting protein, however, this assumption is not supported or refuted by the data presented.
Intergenic linkage disequilibria A total of 1349 polymorphisms across all five target genes were assigned SIFT, PolyPhen-2, PROVEAN and/or HSF scores. Tests for pairwise LD were performed on this subset of loci to address potential linkage disequilibria between polymorphisms that may alter the activity of multiple proteins. After Bonferroni correction (5.50 × 10 -8 ), 9573 AFR, 1328 AMR, 2517 EAS, 3134 EUR and 2583 SAS significant pairwise LDs were observed between polymorphic loci of different genes (P o0.0004, Supplementary Table 23 ). The number of significant pairwise LDs is less than that due to chance alone (that is,~45 461), however, those that contain two causal polymorphisms may be clinically significant. After removal of significant pairwise LDs containing loci which deviate from HWE expectations, there were 539, 12, 124, 282 and 128 significant pairwise LDs in the AFR, AMR, EAS, EUR and SAS populations, respectively, between polymorphic loci in different genes that are predicted to be damaging, or most likely damaging to the resulting protein ( Figure 5 ). Two polymorphisms are part of 82.2, 98.4, 46.8 and 85.9% of these significant pairwise LDs within AFR, EAS, EUR and SAS, respectively (rs5885589 and rs677830). Rs5885589 is an ABCB1 intronic polymorphism which breaks an existing splice site and activates a cryptic splice site just upstream of exon 17. Rs677830 is found within exon 4 of OPRM1 and confers glutamine411stop in transcript variant 1B5. https://www.ncbi.nlm. nih.gov/nuccore/NM_001145286.2. The AMR population does not have a substantial percentage of pairwise LDs associated with a single polymorphism. Table  9 and concordance with variant effect prediction generated by SIFT, PolyPhen-2, PROVEAN and HSF with green and red cells indicating tolerance and damage, respectively. 
DISCUSSION
Our study is limited by two factors. First, the coverage requirement for the 1000 Genomes Project is~4 × , producing an inherent level of missing variants or error in the sequence data. Second, due to limited size in each sub-population, some rare alleles may not be observed due to sample size. When data are generated in-house with greater sub-population samples sizes, greater coverage can be applied that will reduce the level of error and increase the chance of observing rare alleles. However, our analyses add to the population studies on pharmacogenetically interesting genes at global scale. [46] [47] [48] Potential contributors to the number of significant deviations from HWE expectations that were observed for CYP2D6 and UGT2B7 polymorphisms in the ACB and CHB populations, respectively, are allele drop-out, the effects of selection and/or population substructure. For both sub-populations, some degree of substructure has been reported. [49] [50] [51] The Barbadian (ACB) population has demonstrated a higher degree of substructure relative to other ancestral African populations. 49, 50 The Han Chinese also show some degree of substructure attributed to northern and southern Han populations. It has been shown that the 1000 Genomes CHB population contains individuals from these Han sub-groups. 51 The 1000 Genomes Project contains self-reported healthy individuals and as such, the prevalence of CYP2D6 PM, IM and UM metabolizers may not reflect previously published data sets focusing on cohorts of affected individuals. The principal component analysis plots of EMs explain relatively little variation (5.0 and 3.2%, respectively, for principle components one and two). These data support previous work demonstrating some level of intra-metabolizer status variability as well as intra-subpopulation variability, which is supported by MDS plot of each population.
The CYP2D6 MDS plots show separation of AFR and EAS from the cluster of AMR, EUR and SAS, supporting previously reported clinical differences between these populations. 52 Lack of tight subpopulation (within super-population) clustering supports previous findings that CYP2D6 activity variation may be greater within than between super-populations. 53 For example, the sub-populations within the EAS super-population (CDX, CHB, Southern Han Chinese, KHV and JPT) do not cluster tightly. The MDS plot indicates that the Chinese and Vietnamese populations (CDX, CHB, Southern Han Chinese and KHV) may be different from the Japanese (JPT) population. While minimal, this Asian variability is not novel and may be clinically significant when treating patients of these ancestries. 54 MDS plots of UGT2B7, ABCB1, OPRM1 and COMT show considerably less between super-population clustering, specifically of the SAS, EUR and AMR populations, suggesting that differences in these genes may be somewhat associated to super-populations. MDS plots of~15 000 polymorphisms do not show sub-population clustering with their respective superpopulations. This observation may be explained by the extreme allele frequency differences between sub-populations of the same super-population. For example, the OPRM1 SNP, rs66579098, has alternate allele frequencies of 0.27, 0.33, 0.52 and 0.78 in the PUR, CLM, MXL and PEL sub-populations, respectively (belonging to the AMR super-population).
26,55
Tests for pairwise LD of damaging, or likely damaging, polymorphisms in all five genes showed association between polymorphisms from all genes. The rs677830 (OPRM1) and rs5885589 (ABCB1) account for a substantial percentage of significant pairwise LDs in the AFR, EAS, EUR and SAS populations. These significant LDs may be clinically relevant due to the potential for multilocus interactions. 44 To our knowledge, rs677830 and rs5885589 have not been reported as causal polymorphisms. Interactions between these loci, or others, may be responsible for compensation when a damaging polymorphism dramatically alters normal protein activity, as suggested by Bartošová et al. 56 and Barratt et al. 57 with ABCB1 and OPRM1 polymorphisms shown to alter protein activity in vivo.
In conclusion, baseline population summary statistics are presented on five genes involved in opiate metabolism that have been implicated in phenotypic variability leading to idiosyncratic responses in patients. This study demonstrates some genetic association between CYP2D6 and UGT2B7, ABCB1, OPRM1 and COMT that will be important for future pharmacogenetic studies and combinatorial genetic approaches for patient care.
